Comparative Pathogenesis of Autoimmune Diabetes in Humans, NOD Mice, and Canines: Has a Valuable Animal Model of Type 1 Diabetes Been Overlooked?
Overview
Authors
Affiliations
Despite decades of research in humans and mouse models of disease, substantial gaps remain in our understanding of pathogenic mechanisms underlying the development of type 1 diabetes. Furthermore, translation of therapies from preclinical efforts capable of delaying or halting β-cell destruction has been limited. Hence, a pressing need exists to identify alternative animal models that reflect human disease. Canine insulin deficiency diabetes is, in some cases, considered to follow autoimmune pathogenesis, similar to NOD mice and humans, characterized by hyperglycemia requiring lifelong exogenous insulin therapy. Also similar to human type 1 diabetes, the canonical canine disorder appears to be increasing in prevalence. Whereas islet architecture in rodents is distinctly different from humans, canine pancreatic endocrine cell distribution is more similar. Differences in breed susceptibility alongside associations with MHC and other canine immune response genes parallel that of different ethnic groups within the human population, a potential benefit over NOD mice. The impact of environment on disease development also favors canine over rodent models. Herein, we consider the potential for canine diabetes to provide valuable insights for human type 1 diabetes in terms of pancreatic histopathology, impairment of β-cell function and mass, islet inflammation (i.e., insulitis), and autoantibodies specific for β-cell antigens.
Wu X, Cheong L, Yuan L, Jin L, Zhang Z, Xiao Y Adv Sci (Weinh). 2024; 11(30):e2308461.
PMID: 38884133 PMC: 11321687. DOI: 10.1002/advs.202308461.
Vaitaitis G, Webb T, Webb C, Sharkey C, Sharkey S, Waid D Front Immunol. 2024; 14:1319947.
PMID: 38318506 PMC: 10839093. DOI: 10.3389/fimmu.2023.1319947.
Development of a requirement for exogenous insulin treatment in dogs with hyperglycemia.
DiNinni A, Hess R J Vet Intern Med. 2024; 38(2):980-986.
PMID: 38205886 PMC: 10937471. DOI: 10.1111/jvim.16990.
Batdorf H, Lawes L, Richardson J, Burk D, Dupuy S, Karlstad M Am J Physiol Endocrinol Metab. 2023; 325(4):E336-E345.
PMID: 37610410 PMC: 10642984. DOI: 10.1152/ajpendo.00033.2023.
Atkinson M, Mirmira R Cell Metab. 2023; 35(9):1500-1518.
PMID: 37478842 PMC: 10529265. DOI: 10.1016/j.cmet.2023.06.018.